A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...

In this edition of InnovationRx, medical debts will be erased from credit histories, this farm is doubling down on raw milk ...

Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetrationEnrolling ...

Dame Esther responded after a columnist tried to use her own cancer experience as an argument against assisted dying.

Beth Sandy, MSN, CRNP, FAPO, led a discussion on EGFR-mutated non-small cell lung cancer, focusing on targeted therapies for ...

Johnson & Johnson (J&J) has reported positive topline outcomes from the Phase III MARIPOSA trial of Rybrevant ...

The other day, Dame Esther Rantzen announced some wonderful news. In an article she’d written for a national newspaper, ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The non-small cell lung cancer (NSCLC) drug osimertinib (Tagrisso) was associated with an increased risk of therapy ...

Cullinan Therapeutics’ strong financial position funds growth into 2028. Find out why CGEM stock presents a compelling buy ...

Johnson & Johnson released results from a phase 3 study, showing that the combination of Rybrevant and Lazcluze significantly improved overall survival in patients with advanced non-small cell lung ...

As a wave of volatility has been re-introduced to the system, investors are flocking toward blue-chip companies for stability ...

China National Medical Products Administration (NMPA) has granted acceptance and priority review for the new drug application ...